Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.64 AUD | -3.03% | -1.54% | +19.63% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 12-04-30 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Thomas Jarrett
COO | Chief Operating Officer | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 12-09-30 |
Justin Ward
BRD | Director/Board Member | - | 15-12-31 |
Director/Board Member | - | 17-11-28 | |
Daniel Astudillo
SAM | Sales & Marketing | - | 18-03-31 |
Maggie Niewidok
SEC | Corporate Secretary | - | 22-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Prendergast
CHM | Chairman | 70 | 18-04-23 |
Alan Dunton
BRD | Director/Board Member | 70 | 20-07-13 |
Director/Board Member | - | 17-11-28 | |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 12-09-30 |
James Graham
CEO | Chief Executive Officer | - | 12-04-30 |
Justin Ward
BRD | Director/Board Member | - | 15-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 203,701,863 | 125,456,123 ( 61.59 %) | 0 | 61.59 % |
Company contact information
Recce Pharmaceuticals Ltd.
Salesforce Tower 180 George Street
2000, Sydney
+61 2 9256 2505
http://www.recce.com.auSector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.63% | 87.41M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- RCE Stock
- Company Recce Pharmaceuticals Ltd